Clinical trial readout dates for Neurocrine Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.
| Phase 2 NBI-1065890 Tardive Dyskinesia · NCT07365462 | February 2027 Recruiting |
| Phase 3 NBI-1065845 Major Depressive Disorder · NCT06963021 | July 2027 Recruiting |
| Phase 3 NBI-1065845 Major Depressive Disorder · NCT06786624 | July 2027 Recruiting |
| Phase 3 NBI-1065845 Major Depressive Disorder · NCT06911112 | July 2027 Recruiting |
| Phase 2 NBI-1117570 Schizophrenia · NCT07288333 | August 2027 Recruiting |
| Phase 3 NBI-1117568 Schizophrenia · NCT06963034 | October 2027 Recruiting |
| Phase 3 NBI-1117568 Schizophrenia · NCT07105098 | November 2027 Recruiting |
| Phase 2 NBI-1117568 Bipolar I Disorder; Mania · NCT07288320 | February 2028 Recruiting |
Neurocrine Biosciences Inc. reported $790M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). It reported net income of $206M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |